Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies.
On the basis of the role of immuno-mediated inflammation in atherosclerosis we investigated, (1) the prevalence of anti-endothelial cell antibodies (AECA) in ischaemic heart disease (IHD); (2) if beta2-glycoprotein I (beta2-GPI) was the target antigen of AECA; (3) the relationship between AECA, tissue factor (TF) and tissue factor pathway inhibitor (TFPI). In 93 consecutive IHD patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and 105 controls AECA were detected by ELISA on human umbilical vein endothelial cells (HUVEC). AECA positive sera were evaluated for anti-beta2-GPI antibodies by ELISA. TF and TFPI plasma levels were assessed by ELISA. Twelve of 93 (12.9%) IHD patients and only one of 105 controls (0.95%) were AECA positive. The prevalence of AECA was higher in unstable angina (UA) than in effort angina (EA) (P=0.01). Three of 12 AECA positive sera resulted positive for anti-beta2-GPI and showed a marked decrease in EC-binding when tested on HUVEC cultured in serum-free medium. The binding was restored by the addition of beta2-GPI. TF and TFPI levels were similar in AECA positive and AECA negative patients. The rate of angiographically documented clinical recurrences was 66.7% in the AECA positive and 14.8% in the AECA negative group (P=0.0004) with a significant relationship between restenosis and AECA (P<0.0001), unchanged by the inclusion of cardiovascular risk factors in the regression model. Our results suggest a 'role' for AECA in the immune-mediated inflammation in UA beta2-GPI is not the only AECA target antigen. AECA are not responsible for high TF and TFPI levels. The high rate of clinical recurrences after PTCA, confirmed by angiography, in AECA positive patients is in line with such a role and suggests further large-scale 'ad hoc' studies.
Farsi
A
A
Istituto di Clinica Medica Generale e Cardiologia, University of Florence, Viale Morgagni 85, 50134, Florence, Italy.
Domeneghetti
M P
MP
Brunelli
T
T
Gori
A M
AM
Fedi
S
S
Gensini
G F
GF
Giglioli
C
C
Prisco
D
D
Passaleva
A
A
Meroni
P L
PL
Del Papa
N
N
Abbate
R
R
D015906:Angioplasty, Balloon, Coronary; D001053:Apolipoproteins / Q000276:immunology / Q000378:metabolism; D001323:Autoantibodies / Q000276:immunology*; D015415:Biomarkers; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D065427:Factor Xa Inhibitors; D005260:Female; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008074:Lipoproteins / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013925:Thromboplastin / Q000276:immunology / Q000378:metabolism; D014471:Umbilical Veins / Q000378:metabolism; D053482:beta 2-Glycoprotein I
D001053:Apolipoproteins; D001323:Autoantibodies; D015415:Biomarkers; D065427:Factor Xa Inhibitors; D006023:Glycoproteins; D008074:Lipoproteins; C087589:anti-endothelial cell antibody; D053482:beta 2-Glycoprotein I; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin